Catalyst Dossier · compiled by CeliA 🧫

TAKEDA PHARMACEUTICAL CO LTD (TAK)

Pharmaceutical Preparations · market cap $48.9B · as of 2026-06-24

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-16 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Takeda Pharmaceutical (TAK) is a Japanese multinational pharma ranked among the global top 20 by revenue, with a diversified pipeline spanning oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies, and vaccines. The company carries a ~$48.9B market cap at ~$15.84/share and has a dense near-term catalyst calendar running from a July 2026 earnings print through multiple Phase 3 readouts and two PDUFAs into mid-2027. Two Phase 3 trials reported positive results as recently as June 5, 2026.

The catalyst path

2026-07-16 (est.)Phase 2 · TAK-360imp 7/10
2026-07-30Earningsimp 5/10
2026-10-31 (est.)Phase 2 · TAK-788imp 7/10
2026-11-10PDUFA · TAK-771imp 9/10
2026-12-31 (est.)Phase 3 · Maribavirimp 9/10
2027-01-01 (est.)PDUFA · Potential Polycythemia Vera Treatmentimp 8/10
2027-02-10 (est.)Phase 3 · Teduglutideimp 9/10
2027-03-16 (est.)Phase 3 · TAK-755imp 9/10

Pipeline

Asset	Phase	Indication
Azacitidine	Phase 3	Myelodysplastic Syndrome
REPLAGAL	Phase 3	Fabry Disease
IGSC 20% infusion	Phase 3	Primary Immunodeficiency Disease
Alogliptin and pioglitazone	Phase 3	Type 2 Diabetes Mellitus
HYQVIA	Phase 3	Primary Immunodeficiency Diseases (PID)
Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)	Phase 2	Dengue Fever
Leuprorelin acetate	Phase 2	Endometriosis
Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.	Phase 3	Hypertension
Lapaquistat acetate and atorvastatin	Phase 3	Hypercholesterolemia
Glyburide	Phase 3	Diabetes Mellitus
Lapaquistat acetate and additional lipid-lowering therapy	Phase 3	Hypercholesterolemia
Vedolizumab	Phase 3	Colitis, Ulcerative
TAK-861	Phase 3	Narcolepsy Type 1
Azilsartan medoxomil and chlorthalidone	Phase 3	Essential Hypertension
Zasocitinib (Dose A)	Phase 2	Hidradenitis Suppurativa
Norwalk VLP vaccine	Phase 2	Acute Gastroenteritis
Glipizide	Phase 3	Diabetes Mellitus
Vortioxetine	Phase 3	Major Depressive Disorder
TAK-881	Phase 3	Primary Immunodeficiency Diseases (PID)
TAK-536	Phase 3	Hypertension

Price & technical context

3-month

-10.7%

6-month

+7.3%

12-month

+9.3%

52-wk range

$13.23–$18.80

vs 50-day MA

+4.1%

vs 200-day MA

+4.6%

Realized vol

23.6%

Max drawdown

-20.1%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for TAK (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.